This enduring program, derived from the virtual live event, aims to improve HCPs knowledge of the rationale for available and emerging TYK2 inhibitors in the treatment of patients with moderate-to-severe plaque psoriasis, as well as improving their clinical skills related to integrating these therapies into clinical practice while addressing healthcare disparities. As such, these “Highlights” cover the key points of the Virtual Live event in a more succinct format designed for online consumption. A link to the full Virtual Live recording for learners who wish to deepen their understanding of the content will be available. As a result of this educational activity, learners should be better able to: 1. Discuss the rationale for targeting TYK2 in the treatment of patients with moderate-to-severe plaque psoriasis 2. Describe the efficacy and safety profiles of available and emerging TYK2 inhibitors in patients with moderate-to-severe plaque psoriasis 3. Explain how TYK2 inhibitors can be integrated into clinical practice to optimize management of patients with moderate-to-severe plaque psoriasis
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/TNT
- Start Date: 2024-10-29 05:00:00
- End Date: 2024-10-29 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Bristol-Myers Squibb Company - Amount: 84758.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all